CD Protein Inhibitors News

«1 2...84 85 86 87 888990 91 92 93 94...3932 3933 »

|||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
Neoadjuvant Chemo-Immunotherapy Followed by Radical Surgery for Synchronous Oligometastatic Non-Small Cell Lung Cancer (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2062;
After a medium follow up of 16.5 months, all the patients were alive without recurrence. Conclusions : Neoadjuvant chemo-immunotherapy and radical surgical treatment seems to be safe and feasible in selected synchronous oligometastatic NSCLC with encouraging mid-term outcomes.

|||||||||| Imfinzi (durvalumab) / AstraZeneca
Consolidative Thoracic Radiotherapy Induced Lymphopenia in Metastatic NSCLC Is Predicted by EDIC and Associated with Poor Clinical Outcomes (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2055;
Severe radiation-induced lymphopenia has been demonstrated to attenuate the PFS and OS benefit of consolidative durvalumab...Short-course, ablative radiation utilizing smaller treatment volumes, lower total radiation doses and more conformal plans may improve outcomes of consolidative radiation by reducing the risk of lymphopenia and preventing immune exhaustion. Further exploration into altered fractionation schedules could lead to improved oncologic outcomes.

|||||||||| Imfinzi (durvalumab) / AstraZeneca
Re-Irradiation with Chemotherapy with/without Immunotherapy for In-Field Local Recurrence Among Lung Cancer Patients (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2045;
The chemotherapy regimens were Paclitaxel and Carboplatin/Cisplatin, repeated every 3 weeks...Compared with the radio-chemotherapy, the combination of ICIs may significantly improve the short-term survival, but not the overall survival. The TRAEs were clinically acceptable and manageable, including the pneumonitis (radiation-induced or ICIs-induced), but attention of bronchial fracture or bleeding must be emphasized.

|||||||||| Tevimbra (tislelizumab-jsgr) / BeiGene
A Retrospective Study of Tislelizumab Combined with Chemotherapy in Patients with Locally Advanced Lung Cancer (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2044;
Immunotherapy combined with chemotherapy is one of the new options for downstaging and conversion therapy for patients with locally advanced lung cancer. It can provide surgical opportunities for patients who have no chance of surgery or who have difficulty in surgery, and can increase the rate of radical surgical resection.

|||||||||| Imfinzi (durvalumab) / AstraZeneca
Outcomes of Durvalumab Consolidation Treatment in Stage III Unresectable NSCLC: A Retrospective Real-World Study (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2043;
Better survival outcomes were observed among patients with PD-L1?50%, those receiving concurrent chemoradiotherapy, and patients with immune-related adverse events. Conclusions : Our study demonstrates that our real-world data not only mirrors the outcomes observed in comparable real-world studies but also surpasses those from the PACIFIC trial regarding the survival advantage of durvalumab consolidation therapy.

|||||||||| Imfinzi (durvalumab) / AstraZeneca
Machine Learning Analysis of Cardiac Sub-Structure Dose and Overall Survival of NSCLC Pts Treated with Concurrent Definitive Chemoradiotherapy (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2042;
Conclusions : Our study demonstrates that our real-world data not only mirrors the outcomes observed in comparable real-world studies but also surpasses those from the PACIFIC trial regarding the survival advantage of durvalumab consolidation therapy. Introduction : We have previously shown that cardiac substructure (CSS) dosimetric parameters (DP) lose significance in linear Cox Proportional Hazards testing after correcting for pt age, PTV volume, and receipt of durvalumab...In ENR, clinical factors predominate, whereas in the other models, various CSS DP

|||||||||| Imfinzi (durvalumab) / AstraZeneca
Toxicity and Outcomes by Radio-Sensitizing Chemotherapy Regimen for Unresectable Stage III NSCLC in British Columbia, Canada (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2041;
Platinum and etoposide (PE) every 3 weeks or weekly carboplatin-paclitaxel (CP) are commonly used radio-sensitizing protocols...The radiosensitizing chemotherapy agents used were cisplatin-etoposide in 82 (41%), carboplatin-etoposide in 49 (24%) and weekly CP in 71 (35%)...Pneumonitis occurred in 23% of our cohort and negatively impacted treatment completion but did not appear to negatively impact survival. There was no difference in pneumonitis rates and overall survival by radio-sensitizing regimen.

|||||||||| Imfinzi (durvalumab) / AstraZeneca
Development of Clinical Prediction Model Using Digital Device for ILD in the Stage III NSCLC Patients Treated with Durvalumab (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2040;
The ROC-AUC decreased when the wearable device data was excluded, and the ROC-AUC was unchanged when the data of cough-counting was excluded. Conclusions : Our findings suggest that it is possible to construct a clinical predictive model with an accuracy at clinically meaningful level for grade 2 or higher ILD in patients receiving durvalumab after CRT, using patients background information and physiological data collected from a wearable device as a feature by the machine-learning methods.

|||||||||| Imfinzi (durvalumab) / AstraZeneca
Safety and Efficacy of Durvalumab Consolidation Therapy after Chemoradiotherapy in NSCLC Patients Positive for Antinuclear Antibodies (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2037;
Conclusions : ANA positivity was a poor prognostic factor in patients receiving durvalumab consolidation therapy after CRT, which may be due to higher frequency of severe pneumonitis. We recommend careful monitoring for pneumonitis during durvalumab consolidation therapy in patients positive for ANA.

|||||||||| Imfinzi (durvalumab) / AstraZeneca
Concurrent Chemoradiotherapy Followed by Durvalumab for Elderly Patients (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2035;
Conclusions : In patients aged above 80 years, consolidation therapy with durvalumab after cCRT is effective, and the completion rate and safety of this therapy are also assured. We will include more patients for further investigation.

|||||||||| Imfinzi (durvalumab) / AstraZeneca
Real World Evidence of Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III NSCLC in Japan: AYAME Study (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2034;
Conclusions : Based on the interim analysis data obtained so far indicate that real-world durvalumab treatment outcomes are consistent with the Japanese subset in the PACIFIC study. We expect that our findings from the updated results will enhance comprehension of the long-term safety and effectiveness of durvalumab in clinical practice.

|||||||||| Ameile (aumolertinib) / Jiangsu Hansoh Pharma
Efficacy and Safety of Aumolertinib with Radiotherapy in the Treatment of Unresectable Locally Advanced EGFR-Mutant NSCLC: A Phase II Study (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2032;
The POLESTAR and LAURA registered clinical study aim to investigate consolidation therapy efficacy and safety of third generation EGFR tyrosine kinase inhibitors (aumolertinib and Osimertinib) after cCRT...Results : The clinical trial is ongoing. Conclusions : The clinical trial is ongoing.

|||||||||| Tevimbra (tislelizumab-jsgr) / BeiGene
Efficacy and Safety of Neoadjuvant Tislelizumab Plus Chemotherapy for the Treatment of Non-Small Cell Lung Cancer: a Pooled Analysis (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2010;
The pooled incidence of all grade TRAEs was 0.89 (95% CI 0.69-1.00), and that of >= grade 3 TRAEs was 0.17 (95% CI 0.05-0.33). Conclusions : According to our analysis, reliable efficacy and safety of neoadjuvant tislelizumab plus chemotherapy for NSCLC were demonstrated across multiple clinical trials.

|||||||||| Tevimbra (tislelizumab-jsgr) / BeiGene
Pathological Response to Neoadjuvant Tislelizumab Plus Chemotherapy in Potentially Resectable Stage IIIB NSCLC (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2008;
7%-89.4%) and 98.7% (95% CI, 92.79%-100.0%), respectively. Table 1: Efficacy results of included patients (N=75) Outcomes n/N (%, 95%CI) Tumor response CR 2/75 (0.03, 0.3-9.3) PR 59/75 (78.7, 67.7-87.3) SD 13/75 (17.3, 9.6-27.8) PD 1/75 (0.01, 0.03-7.2) ORR 61/75 (81.3, 70.7-89.4) DCR 74/75 (98.7, 92.8-100.0) Surgical resection Surgery rate 64/75 (85.3, 75.3-92.4) R0 64/64(100, 94.39-100) Pathologic outcomes pCR 28/64 (43.7, 32.4-56.7) MPR 47/64(73.4,60.91-83.7) Non-MPR 17/64 (26.6, 16.3-30.1) Tumor downstaging 54/64(84.37, 73.13-92.24) Conclusions : Tislelizumab in combination with chemotherapy as neoadjuvant therapy demonstrated promising antitumor activity for potentially resectable stage IIIB NSCLC with high rates of MPR and pCR.

|||||||||| Tyvyt (sintilimab) / Eli Lilly
Neoadjuvant Chemoimmunotherapy for Potentially Resectable IIIA/IIIB NSCLC(Neo-Pre-IC): Survival Updates and Predictive Effect of MRD (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2002;
P2
Conclusions : Neoadjuvant chemoimmunotherapy markedly enhanced the rate of pathological response and 2-year DFS in patients with potentially resectable IIIA/IIIB NSCLC. MRD may serve as a potential predictive biomarker for DFS.

|||||||||| Tecentriq (atezolizumab) / Roche
Real World Outcomes of Adjuvant Atezolizumab in NSCLC: A Single Institution Study (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1992;
The toxicity profile and discontinuation rates were similar to that reported in the global IMpower010 study, suggesting good applicability of evidence from this trial to real world context. Further follow-up will be required to assess the ability of adjuvant atezolizumab to promote DFS.

|||||||||| Opdivo (nivolumab) / BMS
Analysis of Variables Predicting pCR and irAEs in Resectable NSCLC Receiving Neoadjuvant Immunotherapy with Chemotherapy (Pre-PLaN) (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1988;
Patients will be treated with NA nivolumab plus platinum doublet chemotherapy...The secondary objectives are to assess pCR, major pathological response (MPR), objective response rates (ORRs), and irAEs; to evaluate exploratory and entirely novel potential biomarkers for predicting responses and irAEs and to assess if a post-treatment (pre-surgery) complete metabolic response by F18-FDG-PET-CT and a blood-only molecular residual disease assay can accurately predict a pCR. Baseline and treatment-emergent potentially predictive variables Category Variables Demographic age, gender, ethnicity, smoking status, vaccination, COVID status Clinical comorbidities, medications (steroids and proton pump inhibitors), weight loss, stage, body mass index Radiology body composition, CT scan, SUV (PET/CT), radiomics, volumetrics Blood-based biomarkers and proteomics flowcytometry (immune cell subsets), immune activation markers, LDH and its isoenzymes, CEA, CA199, CA125, leukemia inhibitory factor (LIF), CRP, IL6, IL7, growth differentiation factor 15 (GDF-15), circulating tumor DNA Pathology and genomics histology, PD-L1, mulitiplex immunohistochemistry (IHC) for tumor microenvironment cell types and proteins (LAG3, lysine specific demethylase (LSD1), and CD47), next generation sequencing (NGS) (Tumour Mutational Burden), spatial transcriptomics, pCR, MPR, faecal and tumour microbiome

|||||||||| Tagrisso (osimertinib) / AstraZeneca, Opdivo (nivolumab) / BMS, Alecensa (alectinib) / Roche
Real-World Outcomes of Patients with Resectable Early-Stage Non-Small Cell Lung Cancer Treated with Neoadjuvant Chemoimmunotherapy (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1948;
Eighteen (69%) received carboplatin/pemetrexed, 6 (23%) carboplatin/paclitaxel, and 2 (8%) carboplatin/gemcitabine for a median of 3 cycles (range 2-4)...Five (19%) received adjuvant therapy; 3 (12%) nivolumab and 2 (8%) targeted therapies (one osimertinib and one alectinib)...All patients were able to undergo surgical resection via lobectomy suggesting room for outcome improvement. Results from this study corroborate the use of neoadjuvant chemoimmunotherapy in the real-world setting.

|||||||||| Opdivo (nivolumab) / BMS
Neoadjuvant Immuno-Chemotherapy in Resectable Non-Small Cell Lung Cancer - A Retrospective Cohort Study (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1947;
Hence, individualized informed decisions should be made. There is an unmet need of biomarkers/models that can predict pCR/toxicity for better patient selection.

|||||||||| Opdivo (nivolumab) / BMS
Adjuvant Immunotherapy for Patients with Resectable NSCLC after Pathologic Complete Response (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1943;
Table 1. Clinical features of patients Variables Adjuvant immunotherapy group No adjuvant immunotherapy group P value Gender Male 34 (94.4) 24 (88.9) 0.643 Female 2 (5.6) 3 (11.1) Age (yrs) 59 (56-66) 62 (56-66) 0.722 Smoking history Non-smoker 5 (13.9) 5 (18.5) 0.733 Former or current smoker 31 (86.1) 22 (81.5) Clinical TNM stage IB 0 1 (3.7) 0.198 IIA-B 6 (16.7) 3 (11.1) IIIA 19 (52.8) 19 (70.4) IIIB 11 (30.6) 4 (14.8) Histological subtypes Squamouse cell carcinoma 29 (80.6) 22 (81.5) 0.926 Non-squamouse cell carcinoma 7 (19.4) 5 (18.5) Immune checkpoint inhibitors Nivolumab 23 (63.9) 15 (55.6) 0.911 Other ICIs 13 (36.1) 12 (44.4) Median follow-up (month) 24.0 (19.0-30.0) 25.5 (19.0-34.0) 0.856 Recurrence event 2 (5.6) 1 (3.7) 1.000

|||||||||| Opdivo (nivolumab) / BMS
Neoadjuvant Chemoimmunotherapy (CIT) In Resectable Non-Small Cell Lung Cancer (NSCLC): Real-World Treatment Patterns and Surgical Outcomes (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1941;
Improved event-free and overall survival have been demonstrated in clinical trials exploring neoadjuvant and peri-operative CIT; as such, use of neoadjuvant CIT (platinum doublet + nivolumab) has become part of the current treatment paradigm...13% received adjuvant platinum-pemetrexed/paclitaxel post CIT...Treatment protocol completion, surgical outcomes and adverse event rates were similar to pivotal studies. Neoadjuvant CIT delivers meaningful pathological response in a real-world unselected clinical population, with Stage III disease deriving substantial benefit in this context.

|||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
Surgical Factors and Adjuvant Therapy Use after Neoadjuvant Therapy for Patients with Resected Stage II-IIIB(N2) NSCLC (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1940;
Uptake of ICI-based neoadjuvant therapy remains low, but its use does not compromise ability to perform minimally invasive resection. Factors influencing use of adjuvant therapy after neoadjuvant therapy should be more closely examined.

|||||||||| Kaitanni (cadonilimab) / Akesobio
Perioperative Cadonilimab and Chemotherapy in Stage II-IIIA Non-Small-Cell Lung Cancer: Preliminary Results from a Phase II Study (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1934;
P2
Methods : Participants with resectable stage II to IIIA NSCLC received platinum-based chemotherapy (nanoparticle albumin-bound paclitaxel 260mg/m 2 , carboplatin AUC 5) plus cadonilimab (10 mg/kg) administered intravenously every 3 weeks for 3 cycles before surgery, followed by adjuvant cadonilimab intravenously every 3 weeks for 9 cycles...Enrollment is ongoing, and extended follow-up is required to assess event-free survival accurately. (ClinicalTrials.gov number: NCT05377658.)

|||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
The Fibrosis Around the Pulmonary Artery Is Associated with Difficulty in Dissection During Surgery after Systemic Therapy (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1886;
Conclusions : The fibrosis around the PA was associated with difficulty in dissection during anatomical lung resection after preoperative systemic treatment. Further research is needed to determine whether the fibrosis arised in the tumor bed and whether radiological findings can predict a thickening of the fibrous layer.

|||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Effect of Cytotoxic Chemotherapy Following Ipilimumab Puls Nivolumab Combination Therapy for Malignant Pleural Mesothelioma (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1630;
As for safety, serious adverse events were observed in 3 patients, one anaphylactic shock and two grade 3 or higher renal dysfunction, which compelled treatment discontinuation. Conclusions : Our findings suggest that the effectiveness of platinum plus pemetrexed successive to ipilimumab plus nivolumab was comparable to the data of first-line cisplatin plus pemetrexed reported in EMPHACIS study in which the mPFS was 5.7 months.

|||||||||| Opdivo (nivolumab) / BMS
Analysis of Pleiotropic Effects of Nivolumab in Patients with Relapsed Pleural Mesothelioma : A Single Center Retrospective Study (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1628;
Conclusions : The effectiveness of Nivolumab administration for PM in real-world clinical settings in this study was comparable to or greater than previous reports in terms of PFS and OS, and the safety profile was tolerable. Additionally, it became evident that even in late-line treatment, Nivolumab administration should be actively considered for patients with good PS.

|||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Incidence of Pseudoprogression and Hyperprogression in Patients with Pleural Mesothelioma Treated with Ipilimumab and Nivolumab (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1625;
The relatively high incidence of pseudoprogression we observed suggests that in the absence of significant clinical deterioration, PM patients on immunotherapy with suspected disease progression at the initial scan should consider continuing treatment until subsequent imaging is performed. Ongoing analyses evaluate the impact of hyperprogression on overall survival; correlate the incidence of pseudoprogression with objective response rate, response duration, and overall survival; and employ radiomics to discriminate between pseudoprogression and true progression.

|||||||||| bintrafusp alfa (M7824) / EMD Serono, Bavencio (avelumab) / EMD Serono, imifoplatin (PT-112) / Promontory Therap
Predictive Value of Neutrophil-to-Lymphocyte Ratio (NLR) and Absolute Lymphocyte Count (ALC) In Thymic Epithelial Tumors (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1618;
Potential reasons include small cohort size and heavy pretreatment affecting immune response. Long term follow-up in a larger cohort is needed.

|||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Incidence of Pseudoprogression and Hyperprogression in Patients with Pleural Mesothelioma Treated with Ipilimumab and Nivolumab (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1614;
The relatively high incidence of pseudoprogression we observed suggests that in the absence of significant clinical deterioration, PM patients on immunotherapy with suspected disease progression at the initial scan should consider continuing treatment until subsequent imaging is performed. Ongoing analyses evaluate the impact of hyperprogression on overall survival; correlate the incidence of pseudoprogression with objective response rate, response duration, and overall survival; and employ radiomics to discriminate between pseudoprogression and true progression.

|||||||||| Retevmo (selpercatinib) / Eli Lilly
Efficacy of Selpercatinib by RET Fusion Partner in RET+ NSCLC: Results from the LIBRETTO-001 and LIBRETTO-431 Trials (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1604;
P1/2, P3
These data further support early and comprehensive genomic testing to identify RET fusions and use selpercatinib as the first-line therapy in patients with advanced RET+ NSCLC. Table 1: Efficacy of Selpercatinib by Fusion Partner Median PFS, months (95%CI) ORR, [n/N] % (95% CI) ORR, [n/N] % (95% CI) ORR, [n/N] % (95% CI) Median DOR, months (95%CI) RET Fusion Partner Overall (N=415) Overall (N=415) Prior Treatment (N=263) Treatment Nai?ve (N=152) Overall (N=415) KIF5B-RET 19.4 (17.1-22.7) [194/297] 65.3 (59.6-70.7) [96/179] 53.6 (46.0-61.1) [98/118] 83.1 (75.0-89.3) 20.3 (17.5-23.9) CCDC6-RET NE (33.0-NE) [73/88] 83.0 (73.4-90.1) [47/61] 77.0 (64.5-86.8) [26/27] 96.3 (81.0-99.9) NE (28.5-NE) OTHER-RET 16.9 (7.5-NE) [16/30] 53.3 (34.3-71.7) [10/23] 43.5 (23.2-65.5) [6/7] 85.7 (42.1-99.6) 17.6 (5.6-NE)

|||||||||| Tagrisso (osimertinib) / AstraZeneca
The Mechanism Study on a Novel CD3-EGFR Bispecific Antibody Combo Improves Osimertinib-Resistant NSCLC Tumor Environment (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1590;
Comparatively, Mono.mac in the Tri group upregulated pathways related to antigen processing and presentation, antitumor (AT) responses, and macrophage recruitment to the tumor, while downregulating angiogenesis pathways (Ang) as demonstrated in Figure 1G. Conclusions : The additional combination of WBP3425 and Tucidnostat with BC3448 demonstrated a synergistic efficacy to Osimertinib-resistant tumors via a multidimensional reshaping of the microenvironment, potentially offering a comprehensive approach to combat NSCLC resistance.

|||||||||| ipatasertib (RG7440) / Roche
Ipat-Lung: A Multi-Center Phase 2 Study of Ipatasertib Plus Docetaxel in NSCLC Patients who Have Failed or Are Intolerant to 1st Line Immunotherapy (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1573;
Allowing for a 25% censoring rate, we therefore plan to enroll 60 evaluable participants. This study is currently ongoing.

|||||||||| Tevimbra (tislelizumab-jsgr) / BeiGene, Avastin (bevacizumab) / Roche, Aidixi (disitamab vedotin) / Pfizer
RESOLUTION: Phase II Study of Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in Patients with HER2 Alteration Advanced NSCLC (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1571;
Disease response will be assessed by investigator according to RECIST 1.1. Patients enrollment is ongoing.

|||||||||| Opportunities for ADC Development in 2L NSCLC Leveraging Predictive Biomarkers (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1567;
While T-DXd and HER3-DXd have been tested in HER2 and EGFR mutated cohorts, respectively, Dato-DXd use has not shown to be impacted by any specific biomarker. These results indicate the need to identify predictive biomarkers of response for improved patient population selection.

|||||||||| pemetrexed / Generic mfg.
Renal Toxicity in Patients with Non-Small Cell Lung Cancer Receiving Maintenance Therapy with Pemetrexed and Pembrolizuma (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1564;
There was a trend towards less renal events in general with pembrolizumab maintenance therapy. These data suggest that pembrolizumab does not add significant risk of renal toxicity in the maintenance treatment of metastatic NSCLC.

|||||||||| paclitaxel / Generic mfg.
Paclitaxel Liposome Combined with Immunotherapy in the First-Line Treatment of Advanced NSCLC: A Multicenter Real-World Study (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1563;
All patients were co-administered platinum with 92.5% receiving carboplatin...Conclusions : Paclitaxel liposome-based chemotherapy plus immunotherapy demonstrated substantial effectiveness and safety for advanced NSCLC in the real-world setting. The study is currently ongoing.

|||||||||| Opdivo (nivolumab) / BMS
TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1551;
P2
The study is currently ongoing. Similar results for biomarkers were observed in NADIM and NADIM II ChIO cohorts analyzed separately, and were not predictive of patients

|||||||||| Opdivo (nivolumab) / BMS
Perioperative Chemoimmunotherapy Rescue Cold HLA-Deficient Tumors Inducing Strong Immune Responses and Long-Term Survival (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1550;
P2
Here, we studied the relationship of HLA-I tumor status at diagnosis, with tumor microenvironment and clinical outcomes of NSCLC patients treated with perioperative nivolumab plus chemotherapy (ChIO) from NADIM clinical trial (NCT03081689)...Similarly, CD8+ T cells were identified in both HLA-deficient tumors, but activation was only detected in CPR HLA-deficient tumor (CD8A/GZMB/KLRK1). Conclusions : Our findings highlight the activity of perioperative ChIO in NSCLC HLA-deficient tumors, and the potential role of TLS, as well as the coordinated action of helper and cytotoxic T-cells, in tumor resolution.

|||||||||| Opdivo (nivolumab) / BMS
TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1548;
P2
Conclusions : Our findings highlight the activity of perioperative ChIO in NSCLC HLA-deficient tumors, and the potential role of TLS, as well as the coordinated action of helper and cytotoxic T-cells, in tumor resolution. Similar results for biomarkers were observed in NADIM and NADIM II ChIO cohorts analyzed separately, and were not predictive of patients

|||||||||| Opdivo (nivolumab) / BMS
Perioperative Chemoimmunotherapy Rescue Cold HLA-Deficient Tumors Inducing Strong Immune Responses and Long-Term Survival (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1547;
P2
Here, we studied the relationship of HLA-I tumor status at diagnosis, with tumor microenvironment and clinical outcomes of NSCLC patients treated with perioperative nivolumab plus chemotherapy (ChIO) from NADIM clinical trial (NCT03081689)...Similarly, CD8+ T cells were identified in both HLA-deficient tumors, but activation was only detected in CPR HLA-deficient tumor (CD8A/GZMB/KLRK1). Conclusions : Our findings highlight the activity of perioperative ChIO in NSCLC HLA-deficient tumors, and the potential role of TLS, as well as the coordinated action of helper and cytotoxic T-cells, in tumor resolution.

|||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Tecentriq (atezolizumab) / Roche
Low-Level Deletion of Chromosome 19p Genes May Be Sufficient to Drive Histology-Dependent Phenotypes in Lung Cancer (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1544;
Here, deletion of any of these three chr19p genes correlated with worse overall survival, and this was statistically significant for STK11 deletion. Conclusions : Overall, our analyses have found that (1) low-level copy deletion of chr19p genes can contribute to immune phenotypes and (2) there is a histology-specific effect of chr19p loss.

|||||||||| Ariely (adebrelimab) / Jiangsu Hengrui Pharma
Post-hoc Biomarker Analysis of Adebrelimab Plus Chemotherapy and Sequential Radiotherapy as First-Line Therapy for ES-SCLC (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1529;
P2
Conclusions : Genomic and transcriptomic biomarkers of tissue and peripheral blood were discovered. These biomarkers displayed association with clinical benefit of adebrelimab plus chemotherapy and adebrelimab with consolidate TRT, but further verification was warranted.

|||||||||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Exploring Circulating Tumor Antigens as a Faster and Lower Cost Alternative to Circulating Tumor DNA in IMpower150 (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1523;
These biomarkers displayed association with clinical benefit of adebrelimab plus chemotherapy and adebrelimab with consolidate TRT, but further verification was warranted. Both ctDNA and ctA testing were deployed in IMpower150, a randomized phase 3 study comparing chemotherapy against combinations of atezolizumab

|||||||||| Opdivo (nivolumab) / BMS
DSTYK Inhibition as a Novel Strategy for Taxane-Based Chemotherapy Sensitation in Early and Advanced Lung Cancer (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1484;
Methods : In silico analysis to study the differential sensitivity to Paclitaxel, Carboplatin, Pemetrexed and Cisplatin drugs were performed using pan-cancer human cancer cell line DSTYK CN data downloaded from Depmap portal (https://depmap.org/portal/depmap/)...An adjuvant cohort composed of Advanced IV stage lung adenocarcinoma patients treated with Carboplatin+Paclitaxel or Carboplatin+Pemetrexed in first line from VHIO; A neoadjuvant cohort including resectable stage IIIA or IIIB NSCLC tumor samples of patients from NADIM I and NADIM II clinical trials perioperative treated with nivolumab plus chemotherapy (Carboplatin+Paclitaxel)...DSTYK downregulation sensitizes both primary and metastatic lung tumors to Carboplatin+ Paclitaxel+ anti-PD1 treatment in mouse models leading to the cure of 100% of the mice. Conclusions : Our data indicates that DSTYK amplification may be a predictor of resistance to taxane-based treatments and could be an actionable target for lung cancer patients in early or/and advanced stages.

|||||||||| Tecentriq (atezolizumab) / Roche
Patterns of Disease Progression after Atezolizumab Plus Chemotherapy in ES-SCLC: Exploratory Analysis from IMfirst Study (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1442;
P3
These results suggest that No-LTB patients are more likely to experience PD in existing lesions and show a wider range of sites of progression compared to LTB patients. Given the limited sample size, these results should be further validated.

|||||||||| Actinium-225 DOTATATE (RYZ101) / BMS, Tecentriq (atezolizumab) / Roche
RYZ101 (225Ac-DOTATATE) + Carboplatin + Etoposide + Atezolizumab in Somatostatin Receptor Expressing Extensive-Stage Small-Cell Lung Cancer (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1440;
P1
Conclusions : There were no DLTs reported at DL1 (6.5 MBq) and the dose of RYZ101 has been escalated to the next dose level. The study is actively enrolling patients to receive RYZ101 at DL2 (8.3 MBq) and additional safety data will be presented once mature.

|||||||||| AiRuiKa (camrelizumab) / HLB Bio Group
Biomarker Analysis of Camrelizumab Plus Nab-paclitaxel and Carboplatin as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1439;
Conclusions : This study showed that camrelizumab plus nab-paclitaxel and carboplatin might be an alternative option of first-line regimens for ES-SCLC. MUC17 alterations or NEUROG1 expression would serve as potential biomarker for this combination.

|||||||||| Hansizhuang (serplulimab) / Fosun Pharma
Real-World First-Line Serplulimab-Based Immunochemotherapy for Extensive-Stage Small Cell Lung Cancer: The Multicenter ASTRUM-005R Study (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1438;
P3
The occurrence frequency of adverse event of special interest (AESI) was 38.85% (421 events), in which grade ?3 AESIs occupied 15.43%. Conclusions : This cohort study reports the real-world survival outcomes of first-line serplulimab-containing immunochemotherapy regimen in patients with ES-SCLC, offering additional empirical evidence to substantiate the therapeutic value of such combinations while complementing the pivotal data to the ASTRUM-005 clinical trial.

|||||||||| AiRuiKa (camrelizumab) / HLB Bio Group
Preliminary Results of A Phase II Study of Camrelizumab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for LD-SCLC (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1436;
Larger sample sizes and longer follow-up times are required to validate our preliminary results. Trial Registration:Chinese Clinical Trial Registry Identifier: ChiCTR2000032275

|||||||||| monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
MOZART: Phase II Trial of Monalizumab, Durvalumab, and Platinum-based Chemotherapy for First-Line Treatment of Extensive Stage SCLC (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1435;
Exploratory objectives include analyzing association of treatment efficacy with minimal residual disease status, blood- and tissue-based genomic and transcriptomic signatures, tumor infiltrating immune cells, and peripheral blood NK cell and CD8+ T cell activity. The study has completed safety lead-in phase.



	Diseases Companies Products Productz Mechanisms of Action Sites